Survival time in a population-based consecutive series of adult myeloid leukemia - The prognostic impact of karyotype during the time period 1976-1993

Leukemia

Volumn 14, Issue 6, 2000, Pages 1039-1043

  Mauritzson, N ^a   Johansson, B ^a   Albin, M ^a   Rylander, L ^a   Billstrom R ^a   Ahlgren, T ^a   Mikoczy, Z ^a   Stromberg U ^a   Mitelman, F ^a   Hagmar, L ^a   Nilsson, P G ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Acute myeloid leukemia; Age; Gender; Karyotype; Morphology; Survival time

Indexed keywords

ANTHRACYCLINE; CYTARABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE; AGED; ARTICLE; BONE MARROW TRANSPLANTATION; CHROMOSOME 16; CHROMOSOME 3; CHROMOSOME 5; CHROMOSOME 5Q; CHROMOSOME 7; CHROMOSOME ABERRATION; CHROMOSOME DELETION 5; CHROMOSOME INVERSION; CHROMOSOME LOSS; CHROMOSOME TRANSLOCATION 15; CHROMOSOME TRANSLOCATION 17; CHROMOSOME TRANSLOCATION 21; CHROMOSOME TRANSLOCATION 22; CHROMOSOME TRANSLOCATION 8; CHROMOSOME TRANSLOCATION 9; CONTROLLED STUDY; FEMALE; GENDER; HUMAN; KARYOTYPING; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; TIME;

EID: 0034125728     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401788     Document Type: Article

References (44)

1. Heim S, Mitelman F. Cancer Cytogenetics, 2nd edn. Wiley-Liss: New York, 1995.
2. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
3. Kersey JH. Fifty years of studies of the biology and therapy of childhood leukemia. Blood 1997; 90: 4243-4251.
4. Faderl S, Kantarjian HM, Talpaz M, Estrov Z. Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood 1998; 91: 3995-4019.
5. Sakurai M, Sanclberg AA. Prognosis of acute myeloblastic leukemia: chromosomal correlation. Blood 1973; 41: 93-104.
6. Marosi C, Koller U, Koller-Weber E, Schwarzinger I, Schneider B, Jäger U, Vahls P, Nowotny H, Pirc-Danoewinata H, Steger G, Kreiner C, Wagner B, Lechner K, Lutz D, Bettelheim P, Haas OA. Prognostic impact of karyotype and immunologic phenotype in 125 adult patients with de nova AML. Cancer Genet Cytogenet 1992; 61: 14-25.
7. Arthur DC, Berger R, Golomb HM, Swansbury GJ, Reeves BR, Alimena G, Van Den Berghe H, Bloomfield CD, de la Chapelle A, Dewald GW, Garson OM, Hagemeijer A, Kaneko Y, Mitelman F, Pierre RV, Ruutu T, Sakurai M, Lawler SD, Rowley JD. The clinical significance of karyotype in acute myelogenous leukemia. Cancer Genet Cytogenet 1989; 40: 203-216.
8. Berger R, Bernheim A, Ochoa-Noguera ME, Daniel M-T, Valensi F, Sigaux F, Flandrin G, Boiron M. Prognostic significance of chromosome abnormalities in acute nonlymphocytic leukemia: a study of 343 patients. Cancer Genet Cytogenet 1987; 28: 293-299.
9. Dastugue N, Payen C, Lafage-Pochitaloff M, Bernard P, Leroux D, Huguet-Rigal F, Stoppa AM, Marit G, Molina L, Michallet M, Maraninchi D, Attal M, Reiffers J. Prognostic significance of karyotype in de novo adult acute myeloid leukemia. The BGMT group. Leukemia 1995; 9: 1491-1498.
10. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, Goldstone A. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322-2333.
11. Fourth International Workshop on Chromosomes in Leukemia. Clinical significance of chromosomal abnormalities in acute nonlymphoblastic leukemia. Cancer Genet Cytogenet 1984; 11: 332-350.
12. Keating MJ, Smith TL, Kantarjian H, Cork A, Walters R, Trujillo JM, McCredie KB, Gehan EA, Freireich EJ. Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome. Leukemia 1988; 2: 403-412.
13. Marlton P, Keating M, Kantarjian H, Pierce S, O'Brien S, Freireich EJ, Estey E. Cytogenetic and clinical correlates in AML patients with abnormalities of chromosome 16. Leukemia 1995; 9: 965-971.
14. Plantier I, Lai JL, Wattel E, Bauters F, Fenaux P. Inv(6) may be one of the only 'favorable' factors in acute myeloid leukemia: a report on 19 cases with prolonged follow-up. Leukemia Res 1994; 18: 885-888.
15. Seeker-Walker LM, Mehla A, Bain B. Abnormalities of 3q21 and 3q26 in myeloid malignancy: a United Kingdom Cancer Cytogenetic Group study. Br J Haematol 1995; 91: 490-501.
16. Mauritzson N, Johansson B, Albin M, Billström R, Ahlgren T, Mikoczy Z, Nilsson PG, Hagmar L, Mitelman F. A single-center population-based consecutive series of 1500 cytogenelically investigated adult hematologic malignancies: karyotypic features in relation to morphology, age and gender. Eur J Haematol 1999; 62: 95-102.
17. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Gallon DAG, Gralnick HR, Sultan C. Proposals for the classification of the acute leukaemias. Br J Haematol 1976; 33: 451-458.
18. Bennett IM, Catovsky D, Daniel MT, Flandrin G, Gallon DA, Gralnick HR, Sultan C. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103: 460-462.
19. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Gallon DAG, Gralnick HR, Sultan C. Criteria for the recognition of minimally differentiated acute myeloid leukaemia (AML-M0). Br J Haematol 1991; 78: 325-329.
20. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Gallon DA, Gralnick HR, Sultan C. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103: 620-625.
21. Ost A, Reizenstein P. Minimal diagnostic criteria for the myelodysplastic syndrome. Leukemia Res 1992; 16: 9-11.
22. ISCN (1995). An International System for Human Cytogenetic Nomenclature. Mitelman F (ed). S Karger: Basel, 1995.
23. Clayton D, Hills M. Statistical Models in Epidemiology. Oxford University Press: New York, 1993.
24. Li Y-S, Khalid G, Hayhoe FGJ. Correlation between chromosomal pattern, cytological subtypes, response to therapy, and survival in acute myeloid leukemia. Scand J Haematol 1983; 30: 265-277.
25. Mitus AJ, Miller KB, Schenkein DP, Ryan HF, Parsons SK, Wheeler C, Antin I. Improved survival for patients with acute myelogenous leukemia. J Clin Oncol 1995; 13: 560-569.
26. de Nully Brown P, Jurlander J, Pedersen-Bjergaard J, Victor MA, Geisler CH. The prognostic significance of chromosomal analysis and immunophenotyping in 117 patients with de novo acute myeloid leukemia. Leukemia Res 1997; 21: 985-995.
27. Bloomfield CD, Shuma C, Regal L, Philip PP, Hossfeld DK, Hagemeijer AM, Garson OM, Peterson BA, Sakurai M, Alimena G, Berger R, Rowley ID, Ruutu T, Mitelman F, Dewald GW, Swansbury J. Long-term survival of patients with acute myeloid leukemia. Cancer Suppl 1997; 80: 2191-2198.
28. Fenaux P, Prendhomme C, Lai JL, Morel P, Beuscart R, Bauters F. Cytogenetics and their prognostic value in de novo acute myeloid leukaemia: a report on 283 cases. Br J Haematol 1989; 73: 61-67.
29. Schiffer CA, Lee El, Tomiyasu T, Wiernik PH, Testa JR. Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia, Blood 1989; 73: 263-270.
30. Tien H-F, Wang C-H, Lin M-T, Lee F-Y, Lin M-C, Chuang S-M, Chen Y-C, Shen M-C, Lin K-H, Lin D-T. Correlation of cytogenetic results with immunophenotype, genotype, clinical features, and ras mutation in acute myeloid leukemia. A study of 235 Chinese patients in Taiwan. Cancer Genet Cytogenet 1995; 84: 60-68.
31. Tashiro S, Kyo T, Tanaka K, Oguma N, Hashimoto T, Dohy H, Kamada N. The prognostic value of cytogenetic analyses in patients with acute nonlymphocytic leukemia treated with the same intensive chemotherapy. Cancer 1992; 70: 2809-2815.
32. Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R, Patil SR, Davey FR, Berg DT, Schiffer CA, Arthur DC, Mayer RJ. Frequency of prolonged remission duration after highdose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998; 58: 4173-4179.
33. Weh HJ, Kuse R, Hoffmann R, Seeger D, Suciu S, Kabisch H, Ritter J, Hossfeld DK. Prognostic significance of chromosome analysis in de novo acute myeloid leukemia (AML). Blut 1988; 56: 19-26.
34. Stasi R, Del Poeta G, Masi M, Tribalto M, Venditti A, Papa G, Nicoletti B, Vernole P, Tedeschi B, Delaroche J, Mingarelli R, Dallapiccola B. Incidence of chromosome abnormalities and clinical significance of karyotype in de novo acute myeloid leukemia. Cancer Genet Cytogenet 1993; 67: 28-34.
35. Musilova J, Michalova K, Zemanova Z, Brezinova Z, Dohnalova A, Sajdova J. Cytogenetic study of acute myeloid leukemia: comparison of data obtained in 1991-1996 and 1982-1988. Neoplasma 1998; 45: 292-295.
36. Estey E, deLima M, Strom S, Pierce S, Freireich EJ, Keating MJ. Long-term follow-up of patients with newly diagnosed acute myeloid leukemia treated at the University of Texas MD Anderson Cancer Center. Cancer 1997; 80: 2176-2180.
37. The Swedish Cancer Registry. Cancer Incidence in Sweden 1996. Norstedts: Stockholm, 1998.
38. Bloomfield CD. Prognostic factors for selecting curative therapy for adult acute myeloid leukemia. Leukemia 1992; 6 (Suppl. 4): 65-67.
39. Head D, Kopecky KJ, Weick J, Files JC, Ryan D, Foucar K, Montiel M, Bickers J, Fishleder A, Miller M, Spier C, Hanson C, Bitter M, Braziel R, Mills G, Welborn J, Williams W, Hewlett J, Willman C, Appelbaum F. Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia. Blood 1995; 86: 1717-1728.
40. Stasi R, Venditti A, Del Poeta G, Aronica G, Dentamaro T, Cecconi M, Stipa E, Scimò MT, Masi M, Amadori S. Intensive treatment of patients age 60 years and older with de novo acute myeloid leukemia. Cancer 1996; 77: 2476-2488.
41. Zittoun R, Cadiou M, Bayle C, Suciu S, Solbu G, Hayat M. Prognostic value of cytologic parameters in acute myelogenous leukemia. Cancer 1984; 53: 1526-1532.
42. Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen I-M, Head DR, Appelbaum FR, Willman CL. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997; 89: 3323-3329.
43. Baudard M, Mane JP, Cadiou M, Viguie F, Zittoun R. Acute myelogenous leukaemia in the elderly: retrospective study of 235 consecutive patients. Br J Haematol 1994; 86: 82-91.
44. Büchner T, Heinecke A. The role of prognostic factors in acute myeloid leukemia. Leukemia 1996; 10 (Suppl. I): S28-29.